
    
      This is a randomized, placebo-controlled, multi-center, partially blinded [i.e., 100 mcg and
      200 mcg IC43 with Al(OH)3,, respectively] and placebo, but unblinded for non-adjuvanted IC43
      [i.e., 100 mcg w/o Al(OH)3] phase 2 pilot study. The study population consists of male or
      female ICU patients with a need for mechanical ventilation for more than 48 hours, aged
      between 18 and 80 years.
    
  